UB
ACAD icon

UMB Bank’s Acadia Pharmaceuticals ACAD Stock Holding History

UMB Bank’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Buy
435
+8
+2% +$176 ﹤0.01% 1904
2026
Q1 		$9.51K Sell
427
-178
-29% -$4.25K ﹤0.01% 1873
2025
Q4 		$16.2K Buy
605
+135
+29% +$3.23K ﹤0.01% 1632
2025
Q3 		$10K Buy
470
+151
+47% +$3.57K ﹤0.01% 1674
2025
Q2 		$6.88K Sell
319
-142
-31% -$2.64K ﹤0.01% 1731
2025
Q1 		$7.66K Buy
+461
New +$8.38K ﹤0.01% 1634
2022
Q2 		– Sell
-794
Closed -$19K – 1891
2022
Q1 		$19K Hold
794
– – ﹤0.01% 1265
2021
Q4 		$18K Buy
+794
New +$16K ﹤0.01% 1300

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UMB Bank's ACAD Position: Q2 2026 in Review

UMB Bank increased its Acadia Pharmaceuticals (ACAD) stake by 1.9% in Q2 2026, buying an estimated $176 and bringing the position to 435 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #1904.

UMB Bank first reported a position in ACAD in Q4 2021 and has held it in 8 quarters since. The position peaked at $19K in Q1 2022. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • UMB Bank held 435 shares of Acadia Pharmaceuticals worth $11K as of Q2 2026.
  • UMB Bank bought 8 Acadia Pharmaceuticals shares in Q2 2026, an estimated $176.
  • Acadia Pharmaceuticals made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1904 holding.
  • UMB Bank first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
  • UMB Bank's Acadia Pharmaceuticals position peaked at $19K in Q1 2022.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.